Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suclear is a brand name for a bowel preparation agent used as an osmotic laxative to cleanse the colon prior to colonoscopy. In the context of the South Korean market and clinical trials (e.g., NCT02551198), Suclear refers to an oral sulfate solution (OSS) composed of sodium sulfate, potassium sulfate, and magnesium sulfate. It works by creating an osmotic gradient that draws water into the intestinal lumen, thereby increasing stool volume and promoting evacuation. While the brand name Suclear was also used in the United States for a combination kit containing both an oral sulfate solution and a polyethylene glycol (PEG-3350) with electrolytes solution (developed by Braintree Laboratories and coded as BLI850), the Korean formulation marketed by Taejoon Pharm focuses on the sulfate solution. Clinical studies have demonstrated that the OSS formulation provides effective bowel cleansing with a lower volume of fluid compared to traditional 4L PEG solutions, often administered in a split-dose regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfate + potassium sulfate + magnesium sulfate (Taejoon Pharmaceutical Co., Ltd.).